相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
Futa Mimoto et al.
MABS (2013)
Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
Jens H. W. Pahl et al.
CLINICAL CANCER RESEARCH (2012)
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
Christian Klein et al.
MABS (2012)
Dual targeting strategies with bispecific antibodies
Roland E. Kontermann
MABS (2012)
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement
Fubin Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
Roland Repp et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Bispecific antibodies for cancer therapy The light at the end of the tunnel?
Patrick Chames et al.
MABS (2009)
Transient expression and purification of chimeric heavy chain antibodies
Jianbing Zhang et al.
PROTEIN EXPRESSION AND PURIFICATION (2009)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer
G. Esendagli et al.
LUNG CANCER (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Outlook - Development trends for monoclonal antibody cancer therapeutics
Janice M. Reichert et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity
Kazuhiro Masuda et al.
MOLECULAR IMMUNOLOGY (2007)
Modulation of therapeutic antibody effector functions by glycosylation engineering:: Influence of Golgi enzyme localization domain and co-expression of heterologous β1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II
C Ferrara et al.
BIOTECHNOLOGY AND BIOENGINEERING (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Divergent immunoglobulin G subclass activity through selective Fc receptor binding
F Nimmerjahn et al.
SCIENCE (2005)
Energy functions for protein design: Adjustment with protein-protein complex affinities, models for the unfolded state, and negative design of solubility and specificity
N Pokala et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
A revival of bispecific antibodies
P Kufer et al.
TRENDS IN BIOTECHNOLOGY (2004)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
PA Albertsson et al.
TRENDS IN IMMUNOLOGY (2003)
Multiple sequence alignment with the Clustal series of programs
R Chenna et al.
NUCLEIC ACIDS RESEARCH (2003)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1
M Hezareh et al.
JOURNAL OF VIROLOGY (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex
P Sondermann et al.
NATURE (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
